Time to first moderate or severe exacerbation All participants · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in time to first moderate or severe exacerbation All participants compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations All… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in SGRQ total score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
FEV1 · people with asthma
1 finding from 1 review
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma
1 finding from 1 review
FEV1 · people with asthma
1 finding from 1 review
Serious adverse events · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review